Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has received an average recommendation of “Moderate Buy” from ...

In the United States, the market has experienced a 3.5% decline over the last week, yet it remains up by 5.8% over the past year with earnings expected to grow annually by 14%. In this context of ...

Piper Sandler analyst Biren Amin maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) today and set a price target of $46.00.

Data demonstrated multiple clinical benefits beyond linear growth— NDA supported by data from three randomized, double-blind, ...